Flecainide acetate and Skin discoloration - a phase IV clinical study of FDA data

Summary:

Skin discoloration is found among people who take Flecainide acetate, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Flecainide acetate and have Skin discoloration. It is created by eHealthMe based on reports of 5,413 people who have side effects when taking Flecainide acetate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

5,413 people reported to have side effects when taking Flecainide acetate.
Among them, 21 people (0.39%) have Skin discoloration.


What is Flecainide acetate?

Flecainide acetate has active ingredients of flecainide acetate. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 6,289 Flecainide acetate users for its effectiveness, alternative drugs and more.

What is Skin discoloration?

Skin discoloration is found to be associated with 2,193 drugs and 1,333 conditions by eHealthMe.

Number of Flecainide acetate and Skin discoloration reports submitted per year:

Could Flecainide acetate cause Skin discoloration?

Time on Flecainide acetate when people have Skin discoloration *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Skin discoloration when taking Flecainide acetate *:

  • female: 57.14 %
  • male: 42.86 %

Age of people who have Skin discoloration when taking Flecainide acetate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 21.43 %
  • 50-59: 14.29 %
  • 60+: 64.29 %

Common drugs people take besides Flecainide acetate *:

  1. Spironolactone: 7 people, 33.33%
  2. Vicodin: 6 people, 28.57%
  3. Lasix: 6 people, 28.57%
  4. Effexor Xr: 6 people, 28.57%
  5. Coumadin: 6 people, 28.57%
  6. Hyzaar: 6 people, 28.57%
  7. Xanax: 6 people, 28.57%
  8. Novolog: 5 people, 23.81%
  9. Imitrex: 5 people, 23.81%
  10. Magnesium Oxide: 5 people, 23.81%

Common side effects people have besides Skin discoloration *:

  1. Rashes (redness): 7 people, 33.33%
  2. Pain In Extremity: 6 people, 28.57%
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 6 people, 28.57%
  4. Skin Hypopigmentation (loss of skin colour): 5 people, 23.81%
  5. Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 5 people, 23.81%
  6. Pain: 5 people, 23.81%
  7. Mobility Decreased (ability to move is reduced): 5 people, 23.81%
  8. General Physical Health Deterioration (weak health status): 5 people, 23.81%
  9. Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 5 people, 23.81%
  10. Emotional Distress: 5 people, 23.81%

Common conditions people have *:

  1. Prostate Cancer Metastatic: 2 people, 9.52%
  2. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 4.76%
  3. Pain In Extremity: 1 person, 4.76%
  4. Neuroendocrine Tumor: 1 person, 4.76%
  5. Neoplasm Malignant (cancer tumour): 1 person, 4.76%
  6. Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 4.76%
  7. High Blood Pressure: 1 person, 4.76%
  8. Heart Rate Irregular: 1 person, 4.76%
  9. Cough: 1 person, 4.76%
  10. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Flecainide acetate and have Skin discoloration?

Check whether Skin discoloration is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Skin discoloration and when was it recovered:

Expand to all the drugs that have ingredients of flecainide acetate:

Alternative drugs to, pros and cons of Flecainide acetate:

Common Flecainide acetate side effects:

Browse all side effects of Flecainide acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Skin discoloration treatments and more:

COVID vaccines that are related to Skin discoloration:

Common drugs associated with Skin discoloration:

All the drugs that are associated with Skin discoloration:

Common conditions associated with Skin discoloration:

All the conditions that are associated with Skin discoloration:

How the study uses the data?

The study uses data from the FDA. It is based on flecainide acetate (the active ingredients of Flecainide acetate) and Flecainide acetate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: